Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–166 of 166 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: DM Clear all
Not listed No phase listed Observational

DM DEVICE DISRUPTION SURVEY

NCT05050019
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 28, 2026, 5:39 PM EDT
Recruiting No phase listed Observational

Post-Market Clinical Investigation Plan - Collagen Dura Membranes (DM & DMO)

NCT06822920
View directory record Official record
Conditions
Repair of Dura Mater
Interventions
Not listed
Lead sponsor
Collagen Matrix
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 28, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

Study of M5049 in DM and PM Participants (NEPTUNIA)

NCT05650567
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
M5049 dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional

Integrating New Skills Into Diabetes Education With CGM

NCT07463209
View directory record Official record
Conditions
Insulin Dependent Diabetes, Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes Education, Diabetes Care, Type 1 Diabetes (T1D), Type 2 Diabetes Mellitus (T2DM)
Interventions
Three-stage CGM integration program, One-time clinic-based CGM training, Self-directed CGM training
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

NCT02442778
View directory record Official record
Conditions
Agitation in Participants With Dementia of the Alzheimer's Type
Interventions
AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 28, 2026, 5:39 PM EDT
Completed No phase listed Observational

Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes

NCT01190904
View directory record Official record
Conditions
Androgen Deficiency, AD, Erectile Dysfunction, ED, Diabetes Mellitus, Coronary Artery Disease, Coronary Revascularization
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Guttenberg, New Jersey • Elmhurst, New York • Mineola, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 28, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy

NCT01182493
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Pump (Medtronic Minimed Paradigm® VEO)
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Albany, New York • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 28, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?

NCT01925248
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
Whey protein, Placebo group
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 28, 2026, 5:39 PM EDT
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study (DMT SV RRS3)

NCT04260620
View directory record Official record
Conditions
Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 28, 2026, 5:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Feasibility Testing of DM-BOOST Intervention.

NCT04710940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes BOOST, Usual Care
Behavioral
Lead sponsor
Daniel Amante
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 28, 2026, 5:39 PM EDT
Terminated Not applicable Interventional Results available

Effect of Raised CBF During CEA on Cognition in DM Patients

NCT00597545
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Artery Stenosis, Diabetes, Cognitive Dysfunction
Interventions
Carotid endarterectomy, Shunt
Procedure · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 28, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

NCT07111065
View directory record Official record
Conditions
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions
FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
Dietary Supplement
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

NCT00296296
View directory record Official record
Conditions
Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Cyclosporin, Tacrolimus, 'Diabetes Education / Management'
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 28, 2026, 5:39 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

NCT00607646
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Dehydroepiandrosterone, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 28, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional

NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study

NCT06593327
View directory record Official record
Conditions
Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
Interventions
Intensive Prevention Strategy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 28, 2026, 5:39 PM EDT
Completed No phase listed Observational

Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging

NCT03052166
View directory record Official record
Conditions
Breast
Interventions
QT Ultrasound scan
Device
Lead sponsor
QT Ultrasound LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
755 participants
Timeline
2017 – 2020
U.S. locations
2
States / cities
Long Beach, California • Novato, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 28, 2026, 5:39 PM EDT
Recruiting No phase listed Observational

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

NCT07702461
View directory record Official record
Conditions
Obesity & Overweight, Diabetes (DM)
Interventions
Glucagon-Like Peptide-1 Agonist (GLP-1)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

DM-CHOC-PEN Plus Radiation for Brain Tumors

NCT03371004
View directory record Official record
Conditions
Advanced Cancer
Interventions
4-Demethyl-4-cholesteryloxycarbonylpenclomedine
Drug
Lead sponsor
DEKK-TEC, Inc.
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
New Orleans, Louisiana • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 28, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

NCT04628936
View directory record Official record
Conditions
Polymyositis, Dermatomyositis
Interventions
KZR-616
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Beverly Hills, California • Orange, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 28, 2026, 5:39 PM EDT
Completed Not applicable Interventional

The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes

NCT01648244
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
Computer-Assisted Decision Support
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 28, 2026, 5:39 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

NCT06185764
View directory record Official record
Conditions
Myotonic Dystrophy Type 1 (DM1)
Interventions
VX-670, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
San Carlos, California • Gainesville, Florida • Fairway, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 28, 2026, 5:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Type 1 Diabetes Mellitus Effect on Bone Mineral Density

NCT01633684
View directory record Official record
Conditions
Diabetes Mellitus, Osteoporosis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 28, 2026, 5:39 PM EDT